Southwest Oncology Group
Southwest Oncology Group
批准号:
8410098
负责人:
JONATHAN W FRIEDBERG
金额:
$37.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1978
资助国家:
美国
项目状态:
已结题
起止时间:
1978-06-01 至 2013-12-31
关键词:
AdultAdvanced Malignant NeoplasmBasic ScienceCancer BiologyCancer CenterCancer ControlCancer HospitalCancer PatientCaringClinicalClinical TrialsCountryData CollectionDevelopmentDiseaseEducationEnrollmentFacultyGoalsHealthHospitalsInformation DisseminationInvestmentsLaboratory ResearchMalignant - descriptorMalignant NeoplasmsMassachusettsMethodologyModalityNew YorkPatient CarePatientsPhasePopulationPreventionProtocols documentationPublicationsRecruitment ActivityResearch InstituteSiteSouthwest Oncology GroupSupportive careTherapeuticTranslational ResearchUniversitiescancer preventioncancer therapyimprovedinnovationmembermultidisciplinarymultimodalitynovel strategiesoutreachprogramstertiary care
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
The University of Rochester is a health and research institute ideally suited to help achieve the goals of the Southwest Oncology Group (SWOG). These goals include: improve standards of care to adult cancer patients advance the understanding of cancer biology via translational research, promote treatment and supportive care to outreach sites through NCI-supported clinical trial participation, explore innovative multi-modality treatment combinations, support cancer prevention efforts, and refine methodology of clinical cancer trials. Our activity (2002 -to date) as fiinded members of the Southwest Oncology Group, indicates our continuous investment in and commitment to clinical and basic laboratory research, patient care, and education. To date we have enrolled 762 cases and served as study chair or co-chair of 14 SWOG protocols; 27 multidisciplinary members actively participated in one or more committees (seven faculty members served as chair and/or co-chair of 21 committees). Eleven faculty members coordinated or co-coordinated 20 protocols and 2studies currently in development. As we recruit more clinical-scientific faculty and further develop interactive, collaborative, multimodality cancer programs, we plan to produce additional important contributions to SWOG. The University of Rochester SWOG program involves 1) The University's James P. Wilmot Cancer Center and the University's Strong Memorial Hospital, a primary tertiary care center. The Cancer Center and hospital serves a population of approximately 1.4 million people 2) Six outreach facilities located In the regronal Northeast section of the country (contiguous states of New York and Massachusetts) Through this Southwest Oncology Group apphcation, our program continues to support and attain objectives to 1) participatein multi-modal Phase II/III clinical trials, 2) accelerate the advances of cancer therapy in adult patients through increased recruitment, 3) enhance basic science clinical interactions; 4) support cancer control and prevention initiatives, 5) provide wide dissemination of information through quality and timely data collection and publications, 6) continueservice to the administrative agenda of the Southwest Oncology Group.
期刊论文(33)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Phase II evaluation of phenesterin in patients with advanced ovarian cancer.
phenesterin 在晚期卵巢癌患者中的 II 期评估。
DOI:
--
发表时间:
1983
期刊:
Cancer treatment reports
影响因子:
--
作者:
[Bloom,RE, Polivogianis,L, Davis,TE, Bennett,JM, Horton,J]
通讯作者:
Horton,J
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
早期乳腺癌辅助化疗的致白血病潜力:东部肿瘤合作组的经验。
DOI:
10.1200/jco.1995.13.7.1557
发表时间:
1995
期刊:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子:
--
作者:
[Tallman,MS, Gray,R, Bennett,JM, Variakojis,D, Robert,N, Wood,WC, Rowe,JM, Wiernik,PH]
通讯作者:
Wiernik,PH
Phase II trial of gallium nitrate, amonafide and teniposide in metastatic non-small cell lung cancer. An Eastern Cooperative Oncology Group study (E2588).
硝酸镓、阿莫菲德和替尼泊苷治疗转移性非小细胞肺癌的 II 期试验。
DOI:
10.1007/bf00872862
发表时间:
1995
期刊:
Investigational new drugs
影响因子:
3.4
作者:
[Chang,AY, Tu,ZN, Smith,JL, Bonomi,P, Smith,TJ, Wiernik,PH, Blum,R]
通讯作者:
Blum,R
Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.
米托蒽醌和依托泊苷治疗复发性难治性急性非淋巴细胞白血病患者。
DOI:
10.1007/978-3-642-74643-7_61
发表时间:
1990
期刊:
Haematology and blood transfusion
影响因子:
--
作者:
[Rowe,JM, Mazza,JJ, Hines,JD, Cassileth,PA, Oken,MM, Bennett,JM, Andersen,J]
通讯作者:
Andersen,J
Phase II study of m-AMSA in advances malignant melanoma.
m-AMSA 治疗晚期恶性黑色素瘤的 II 期研究。
DOI:
10.1097/00000421-198208000-00015
发表时间:
1982
期刊:
American journal of clinical oncology
影响因子:
--
作者:
[Arseneau,JC, Wolter,JM, Probert,JC, Kuperminc,M]
通讯作者:
Kuperminc,M
共 25 条
Vitamin D and Follicular Lymphoma
-
批准号:9397911
-
项目类别:
-
资助金额:$70.22万
-
财政年份:2017
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Vitamin D and Follicular Lymphoma
-
批准号:9502928
-
项目类别:
-
资助金额:$61.51万
-
财政年份:2017
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Vitamin D and Follicular Lymphoma
-
批准号:10219983
-
项目类别:
-
资助金额:$59.25万
-
财政年份:2017
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
P- 3: Potentiating Proteasome Inhibitor Activity in NHL
-
批准号:7507432
-
项目类别:
-
资助金额:$26.31万
-
财政年份:2008
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
CC: Clinical Trials Core
-
批准号:7507437
-
项目类别:
-
资助金额:$23.54万
-
财政年份:2008
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
PHASE 2, OPEN-LABEL STUDY OF 1018 ISS, FOLLOWING RITUXAN TREATMENT
-
批准号:7200122
-
项目类别:
-
资助金额:$1.27万
-
财政年份:2005
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Monoclonal Antibody Therapy for Follicular Lymphoma
-
批准号:6786000
-
项目类别:
-
资助金额:$13.08万
-
财政年份:2003
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Monoclonal Antibody Therapy for Follicular Lymphoma
-
批准号:7101820
-
项目类别:
-
资助金额:$13.08万
-
财政年份:2003
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Monoclonal Antibody Therapy for Follicular Lymphoma
-
批准号:6674598
-
项目类别:
-
资助金额:$13.08万
-
财政年份:2003
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Monoclonal Antibody Therapy for Follicular Lymphoma
-
批准号:6935922
-
项目类别:
-
资助金额:$13.08万
-
财政年份:2003
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Southwest Oncology Group
-
批准号:8073085
-
项目类别:
-
资助金额:$35.57万
-
财政年份:1978
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
Southwest Oncology Group
-
批准号:8215648
-
项目类别:
-
资助金额:$37.77万
-
财政年份:1978
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)
-
批准号:8131041
-
项目类别:
-
资助金额:$33.39万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)
-
批准号:8381188
-
项目类别:
-
资助金额:$33.52万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
CC: Clinical Trials Core
-
批准号:8381198
-
项目类别:
-
资助金额:$39.09万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
CC: Clinical Trials Core
-
批准号:8321628
-
项目类别:
-
资助金额:$36.98万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
CC: Clinical Trials Core
-
批准号:7905991
-
项目类别:
-
资助金额:$43.67万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)
-
批准号:8321623
-
项目类别:
-
资助金额:$31.74万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
P-3: Potentiating Proteasome Inhibitor Activity in non-Hodgkin's Lymphoma (NHL)
-
批准号:7905986
-
项目类别:
-
资助金额:$37.74万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位:
CC: Clinical Trials Core
-
批准号:8131046
-
项目类别:
-
资助金额:$38.88万
-
财政年份:--
-
负责人:JONATHAN W FRIEDBERG
-
依托单位: